Clinical trial
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating…
NCT00494182 · M.D. Anderson Cancer Center, Other · Active, not recruiting
Key facts
| NCT number | NCT00494182 |
|---|---|
| Title | Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
| Official title | A Phase II Study of Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity, Metastatic Squamous Cell Carcinoma of the Oropharynx, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Carboplatin, Paclitaxel, Sorafenib |
| Enrollment | 48 |
| Start date | Apr 25, 2007 |
| Primary completion | Dec 31, 2026 |
| Completion | Dec 31, 2026 |
| First posted | Jun 29, 2007 |
| Last update posted | Dec 17, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: